Adipose tissue processing & autologous fat transfer systems

Executive summary

Autologous fat transfer, also called fat grafting or lipofilling, is a surgical technique in which a patient’s own adipose tissue is harvested by liposuction, processed to remove tumescent fluid, free oil, blood and debris, and then reinjected as a soft-tissue filler or volume replacement. The processing step is the core of this technology area. Historically, processing was manual — decantation, saline washing, or simple centrifugation. Since the 2000s, closed-loop, single-use processing systems have been commercialized to standardize washing, filtering, and collection in the operating room.

The main technical claim in this area is that controlled, closed-loop processing removes nonviable fractions while preserving adipocyte and stromal vascular fraction viability, which may improve graft take and volume retention. The strongest source-tier evidence for this claim is peer-reviewed surgical literature, but the literature itself reports no universal consensus on the optimal processing method ([J1], [J2]). A granted US patent covers a method for augmenting autologous fat transfer with adipose-derived regenerative cells ([P1]), but that patent is method-level evidence; it does not by itself prove device performance or commercial viability.

Commercially, the public-equity exposure is concentrated: AbbVie owns Allergan Aesthetics, which markets the REVOLVE adipose tissue processing system. Adjacent public companies, such as InMode, provide liposuction or body-contouring platforms used in the same surgical workflow.

Scope and source design

The requested source tiers were applied as follows:

• Tier 1 for technical/performance/IP claims: granted US patent ([P1]), peer-reviewed plastic-surgery reviews ([J1], [J2], [J3]), and regulator databases ([S4], [S5]).
• Tier 2 for adoption/deployment context: company self-reported product pages ([S6]) and SEC filing search pages ([S4]).
• Prohibited sources were not used.

The note distinguishes:

• Granted patents from applications: US 7,390,484 B2 is a granted patent, not a patent application ([P1]).
• Peer-reviewed papers from preprints: Strong 2015 and Gir 2012 are journal articles, not arXiv preprints ([J1], [J2]).

A patent is evidence of recorded claims, not proof of performance. The peer-reviewed literature is the better source for clinical-performance and processing-method disputes.

Clinical and technical background

Autologous fat transfer has three main technical stages:

1. Harvesting — Tumescent liposuction is used to obtain lipoaspirate. The harvested tissue is not pure fat; it contains saline, local anesthetic, blood, free oil from ruptured adipocytes, and fibrous debris ([J1], [J2]).

1. Processing — The lipoaspirate is separated into the fat-graft fraction and unwanted fluid/debris. Processing methods include:

• Gravity decantation: the easiest and cheapest method, but it leaves water and blood in the graft and may lower graft take ([J2]).
• Centrifugation: the Coleman technique popularized centrifugation, classically approximately 3,000 rpm for 3 minutes, to separate layers of oil, purified fat, and aqueous fluid ([J1], [J3]).
• Washing/filtration: closed-loop devices such as REVOLVE and Puregraft filter and wash lipoaspirate in a sterile circuit, reducing open-air handling and manual variability ([J1], [J2]).
• Enzymatic/cell-enrichment processing: systems in the Cytori Celution lineage can isolate adipose-derived regenerative cells, which are then combined with the fat graft to augment retention ([P1]).

1. Reinjection — The processed fat is injected in small aliquots with blunt cannulas to maximize contact with recipient tissue and minimize necrosis ([J1], [J3]).

A recurring technical contradiction in the literature is that high centrifugation speed may damage adipocytes and reduce stem-cell yield, while low-speed or decantation methods may leave excess impurities that provoke inflammation and resorption. Strong et al. describe this as an unresolved trade-off: centrifugation can create the classic three-layer separation, but excess g-force or spin time may damage the graft ([J1]). Gir et al. similarly report that no single processing method is universally superior across comparative studies ([J2]).

Patent landscape

Granted patent: US 7,390,484 B2

The key Tier-1 patent found is:

• US 7,390,484 B2 — “Methods of using adipose tissue-derived cells in augmenting autologous fat transfer.” Assignee: Cytori Therapeutics, Inc. Granted June 24, 2008 ([P1]).

URL: https://patents.google.com/patent/US7390484B2/en

This is a granted US patent, not an application. Its claims are directed to methods in which adipose-derived regenerative cells are combined with a fat graft to augment autologous fat transfer. The patent is important because it anchors the Cytori Celution/regenerative-cell branch of the fat-grafting device field: systems that enzymatically or mechanically process adipose tissue to enrich regenerative cells before injection.

Limitation: This patent does not describe a specific closed-loop hardware design. It is a method patent covering cell-enriched fat grafting. Therefore it should not be cited as proof that any commercial device has superior clinical performance. It is evidence that Cytori recorded claims over cell-enriched autologous fat transfer methods, not proof that the method achieved market adoption or payer coverage.

The current ownership and maintenance status of US 7,390,484 B2 should be confirmed in USPTO assignment records before any investment conclusion is drawn. I could not independently verify current assignee or maintenance fee status under the no-live-browser constraint; this point is marked needs primary source validation.

Applications and unverified patents

There are many later patent applications and granted patents in the closed-loop fat-washing device space, but I did not cite them here because I could not verify a grant number with sufficient confidence under the source-tier rule. If a future pass retrieves a granted device patent for REVOLVE, Puregraft, or Lipogems, it should be added as Tier 1 hardware evidence. Until then, hardware-level patent claims are needs primary source validation.

Peer-reviewed literature

Strong 2015 — a current-state review

Strong AL, Cederna PS, Rubin JP, Coleman SR, Levi B. The current state of fat grafting: a review of harvesting, processing, and injection techniques. Plast Reconstr Surg. 2015;136(4):897-912. doi:10.1097/PRS.0000000000001590 ([J1]).

URL: https://doi.org/10.1097/PRS.0000000000001590

This is a peer-reviewed, journal-published review. It is not a preprint. It covers:

• Tumescent liposuction harvesting.
• Processing methods including centrifugation, filtration, and washing.
• The observation that processing affects cell viability and graft survival.
• The fact that fat graft retention is technique-dependent.

For the worked calculation below, I use the review’s reported one-year graft retention range of 40–80% ([J1]). This range is a literature-derived range; the exact midpoint is a model assumption, not a measured result for a specific device.

Gir 2012 — an evidence-based review

Gir P, Brown SA, Oni G, Kashefi N, Mojallal A, Rohrich RJ. Fat grafting: evidence-based review on autologous fat harvesting, processing, reinjection, and storage. Plast Reconstr Surg. 2012;130(1):249-258. doi:10.1097/PRS.0b013e318254b4d3 ([J2]).

URL: https://doi.org/10.1097/PRS.0b013e318254b4d3

This peer-reviewed review is the main Tier-1 source for the no-consensus finding. It states that the evidence base is heterogeneous and that standard outcome measures are lacking. It also supports the claim that processing choices — centrifugation versus filtration versus decantation — affect final graft composition and potentially clinical survival.

Coleman 2006 — structural fat grafting

Coleman SR. Structural fat grafting: more than a permanent filler. Plast Reconstr Surg. 2006;118(3 Suppl):108S-120S. doi:10.1097/01.prs.0000234610.81672.e7 ([J3]).

URL: https://doi.org/10.1097/01.prs.0000234610.81672.e7

This foundational peer-reviewed article describes the Coleman technique of fat harvesting and centrifugation. It is used here only as background for the manual centrifugation method; it predates most closed-loop commercial systems.

Cross-verification

The independent source requirement is satisfied for the load-bearing claim that processing method matters but no method is clearly superior:

• Strong 2015 ([J1]) — independent academic review.
• Gir 2012 ([J2]) — independent academic review.

Both are from different institutions and author groups, not a company paper + same company patent lineage. The two-source cross-verification is satisfied for the claim that processing method is a subject of active clinical uncertainty.

The patent ([P1]) is a separate lineage and is not used as performance evidence.

Regulatory and company-filing cross-reference

FDA pathway

Autologous fat processing devices are typically Class II medical devices cleared through the 510(k) pathway, not PMA-approved drugs or biologics. The specific 510(k) numbers for REVOLVE and comparable systems should be retrieved from the FDA’s 510(k) Premarket Notification Database ([S5]). Under the no-live-browser constraint, I did not verify the exact K number; it is marked needs primary source validation.

The FDA database is a Tier-1 regulator source for device clearance status:

• US FDA 510(k) Premarket Notification Database ([S5])

URL: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm

AbbVie/Allergan SEC filings

AbbVie Inc. acquired Allergan in May 2020 and now reports Allergan Aesthetics as a business segment. AbbVie’s Form 10-K is the primary Tier-2/regulator source for segment risk factors and competitive disclosure ([S4]):

• US SEC EDGAR — AbbVie Inc. 10-K search ([S4])

URL: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152&type=10-K&dateb=&owner=include&count=40

Cross-reference result / discrepancy: Company marketing may emphasize REVOLVE’s closed-loop control and ease of use. SEC risk factors, by contrast, generally do not provide product-level performance claims or standalone REVOLVE revenue; they discuss broad competition, regulatory clearance risk, and dependence on aesthetics procedure volumes. Under the no-live-browser constraint, I did not retrieve the exact product-level language in the 10-K; this specific discrepancy is needs primary source validation. The structural point is sound: public filings are risk-focused, not marketing archives, so performance claims must be tested against the FDA clearance record and independent clinical literature, not company risk factors.

Clinical-regulatory gap

A device cleared via 510(k) demonstrates substantial equivalence to a predicate device, not independent proof of superior graft retention. This is a Tier-1 regulatory doctrine, and it reinforces the thesis-validity rule used in this note: marketing claims of “better graft take” require independent controlled studies.

Unit economics / business model

Who monetizes

The manufacturers of the processing systems monetize through:

1. Reusable console or platform, if the system has one.
2. Single-use disposable kits, which are consumed per procedure and create recurring revenue.
3. Service and training contracts, where applicable.

In the case of REVOLVE, the commercial model is primarily the single-use disposable processing kit used in a surgical procedure. AbbVie does not separately disclose REVOLVE revenue in its SEC filings ([S4]); therefore, no reliable ASP or gross-margin figure can be stated without primary-source validation. Any specific price or margin is needs primary source validation.

Value capture

• Device/consumable manufacturer captures the per-procedure kit revenue.
• Surgical practice/hospital captures the procedural fee. For cosmetic fat grafting, this is often out-of-pocket; for reconstructive fat grafting after breast cancer, it may be reimbursed. This split is well described in the clinical literature ([J1], [J2]) but specific payment rates are not cited here.
• Patient/insurer ultimately funds the procedure, but the technology’s value is captured mainly by the manufacturer and the provider.

Worked calculation — effective retained graft volume

This calculation models how processing yield and biological retention interact. It does not use vendor-reported prices or vendor-reported device yields.

Formula:

\[

V_{\text{effective}} = V_{\text{harvest}} \times Y_{\text{processing}} \times R_{\text{retention}}

\]

Where:

• \(V_{\text{harvest}}\) = harvested lipoaspirate volume submitted to processing, in mL.
• \(Y_{\text{processing}}\) = fraction of harvested volume retained as injectable graft after fluid/oil removal; unitless.
• \(R_{\text{retention}}\) = one-year retained graft fraction; unitless.

Base case inputs:

• \(V_{\text{harvest}} = 100 \text{ mL}\) — model input; no source needed, labeled assumed.
• \(Y_{\text{processing}} = 0.70\) — assumed closed-loop wash/filter yield; not retrieved from a vendor datasheet, labeled needs primary source validation.
• \(R_{\text{retention}} = 0.60\) — midpoint of the 40–80% one-year retention range reported in [J1]; labeled derived from published range.

Base result:

\[

V_{\text{effective}} = 100 \times 0.70 \times 0.60 = 42 \text{ mL effective retained graft}

\]

Sensitivity:

Interpretation: Moving from poor processing/biology to optimized processing/biology changes effective retained graft volume from 20 mL to 68 mL, a 3.4× difference. This explains why processing systems can command premium pricing if they reliably shift \(Y_{\text{processing}}\) or \(R_{\text{retention}}\) upward. However, the clinical literature has not established that closed-loop devices do this better than optimized manual methods in every site or indication ([J1], [J2]).

Cost per effective retained mL — sensitivity model

Because no public MSRP is available, this is a pure sensitivity illustration, not source-bound pricing evidence.

Formula:

\[

\text{Cost per effective mL} = \frac{C_{\text{kit}}}{V_{\text{effective}}}

\]

Inputs:

• \(C_{\text{kit}}\) = disposable processing kit cost, assumed; needs primary source validation.
• \(V_{\text{effective}}\) from above.

All cost figures are assumptions and must be replaced with actual hospital supply-chain data before use. They are included only to show the sensitivity, not to assert any vendor’s pricing.

Parameter table

Disconfirming Evidence

The thesis that closed-loop adipose processing systems provide durable clinical and economic value would be weakened or falsified by:

1. A randomized controlled trial showing no significant difference in one-year fat graft retention between simple decantation, manual centrifugation, and closed-loop filtration systems.
2. A peer-reviewed meta-analysis finding that processing-method effects on graft survival are small or null after correcting for technique and body site.
3. FDA enforcement action, warning letter, or recall involving a major adipose processing system, which would undermine the safety/sterility rationale for closed-loop devices.
4. Widespread hospital or surgery-center adoption reversal away from capital/disposable systems toward manual methods on cost grounds, which would shrink the recurring-revenue base.
5. Patent invalidation or narrow claim construction of US 7,390,484 B2 or relevant device patents, which would weaken the IP moat.